Marker Therapeutics (MRKR) Net Equity Issued and Repurchased (2011 - 2024)
Marker Therapeutics (MRKR) posted quarterly Net Equity Issued and Repurchased of $14.9 million for Q4 2024, up 1617.08% year-over-year from $867301.6 in Q1 2024, and up 37130.63% quarter-over-quarter from $40000.0 in Q2 2024.
Marker Therapeutics (MRKR) Net Equity Issued and Repurchased (2011 - 2024) Analysis & Trends
Marker Therapeutics (MRKR) has reported Net Equity Issued and Repurchased for 10 consecutive years, with $14.9 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Net Equity Issued and Repurchased rose 1617.08% year-over-year to $14.9 million; the TTM figure through Dec 2025 stood at $14.9 million (up 7.04% YoY), while the FY2025 annual figure was $9.9 million, down 33.93% from the prior year.
- Net Equity Issued and Repurchased grew to $14.9 million in Q4 2024 per MRKR's latest filing, from $40000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $52.7 million in Q1 2021 and bottomed at -$981640.0 in Q4 2023.
- Historically, Net Equity Issued and Repurchased has averaged $6.7 million across 5 years, with a median of $394666.0 in 2023.
- Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased plunged 808.47% — and 2024, when it soared 1617.08%.
- Marker Therapeutics' Net Equity Issued and Repurchased stood at $4.0 million in 2020, then plunged by 102.6% to -$103830.0 in 2021, then soared by 233.45% to $138557.0 in 2022, then slumped by 808.47% to -$981640.0 in 2023, then jumped by 1617.08% to $14.9 million in 2024.
- Business Quant data shows MRKR's Net Equity Issued and Repurchased at $14.9 million in Q4 2024, $40000.0 in Q2 2024, and -$981640.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 14.89 Mn |
| Dec 31, 2024 | 14.89 Mn |
| Jun 30, 2024 | 40,000.00 |
| Jun 30, 2024 | 40,000.00 |
| Dec 31, 2023 | -981,640.00 |
| Dec 31, 2023 | -981,640.00 |
| Sep 30, 2023 | 394,666.00 |
| Sep 30, 2023 | 394,666.00 |
| Mar 31, 2023 | 619,974.00 |
| Mar 31, 2023 | 619,974.00 |
| Dec 31, 2022 | 138,557.00 |
| Dec 31, 2022 | 138,557.00 |
| Jun 30, 2022 | 63,573.00 |
| Jun 30, 2022 | 63,573.00 |
| Jun 30, 2021 | -103,830.00 |
| Jun 30, 2021 | -103,830.00 |
| Mar 31, 2021 | 52.66 Mn |
| Mar 31, 2021 | 52.66 Mn |
| Dec 31, 2020 | 4.00 Mn |
| Dec 31, 2020 | 4.00 Mn |